TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05456256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-300
Description: LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
Study: NCT04753528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuriMod CT01_A
Description: AuriMod CT01 is a wearable medical device for personalised pain treatment through auricular vagus nerve stimulation. AuriMod CT01 is a battery-operated electrical stimulation device, to be placed behind the ear on the neck. AuriMod CT01 connects to three needle electrodes, which are placed in vagally innervated regions of the auricle. It emits electrical signals with a personalized set of stimulation parameters and adjustable amplitude.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuriMod CT01_B
Description: AuriMod CT01 with a fixed set of stimulation parameters and adjustable stimulation amplitude.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AuriMod CT01_C
Description: AuriMod CT01 with a fixed set of stimulation parameters and amplitude.
Study: NCT05965310

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Psychological Intervention: Cognitive Behavioral Therapy
Description: An asynchronous course of pre- and post-operative CBT modules (VPI) will be delivered to patients in Group A as an adjuvant treatment to standard-of-care rehabilitation.
Study: NCT05395936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myocardial Probe Temperature Screen
Description: The myocardial probe is a needle that measures temperatures. The skin site for introducing the myocardial probe will be small enough that participants will not notice that temperatures have been collected. If participants have multiple operations, temperatures may be collected at each operation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data Collection
Description: Study team members will collect medical history and other information to potentially understand the safety and success of breast surgery better to allow investigators to identify variables, or changes to help understand investigators roles in potential complications in breast surgery.
Study: NCT06558071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galatonol 300 mg/Striatin 30 mg
Description: 1 film-coated caplet of Herba Asimor, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 film-coated caplet of placebo Herba Asimor, twice daily
Study: NCT01890941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809 ophthalmic solution
Study: NCT04835181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with umbilical moxibustion
Description: ①Umbilical moxibustion intervention: point selection: Shenque point Operation: Place the aconite cake on the Shenque point, place the Aizhu in the middle of the aconite cake, ignite the Aizhu and apply moxibustion to make the local warm sensation without burning pain, until the skin is flushed.~②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: ②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance.
Study: NCT04989010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-NY005
Description: 89Zr-NY005 injection followed by 89Zr-NY005 PET scan
Study: NCT05889507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole body hypothermia
Description: Whole-body hypothermia (33.5±0.5°C) initiated within 6 hours of birth and continued for 72 hours. The rectal temperature will be maintained at 33.5±0.5°C using a servo-controlled cooling machine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Targeted normothermia
Description: The rectal temperature will be maintained at 36.5±0.5°C using servo-controlled incubators for the first 80 hours and any hyperthermia will be treated with a standardised protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive neonatal intensive care
Description: Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive neonatal intensive care
Description: Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
Study: NCT05834946

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Megagen implant placement
Description: Megagen implant with sand-blasted, large-grit, acid-etched (SLA) and nano-calcium ions incorporated surface
Study: NCT05889507

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Follow up assessment at 2 years of age
Description: The assessment will be carried out using the Bayley Scales of Infant and Toddler Development IV. In addition, all infants will have a detailed neurological examination, including Gross Motor Function Classification System (GMFCS) for cerebral palsy, vision, and hearing assessment. Babies who die or who cannot be assessed with the Bayley-IV due to severe disability will be allocated a Cognitive Scale Composite score one point below the basal test score. PARCA-R will be completed by the parents immediately.
Study: NCT05834946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Megagen implant placement
Description: Megagen implant with sand-blasted, large-grit, acid-etched (SLA) and nano-calcium ions incorporated surface

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomate-Swiss implant
Description: Biomate-Swiss implant with precision dimension laser (PDL) surface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomate-Swiss implant
Description: Biomate-Swiss implant with precision dimension laser (PDL) surface
Study: NCT06460688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother Rehabilitative Aid Education Program
Description: Routine neuro physical therapy will be given which includes Stretching, truck control and independent transition, train standing and activation of base, gain walking with minimal assistance, Gain ground clearance with stair climbing. A class will be organized to educate Mothers/ Caregivers through PPT presentation, video and pictures. This class will contain 3 domains (Counseling, Educating, Practicing). Feedback will be taken on daily basis through video recordings. Mothers will take part in treatment session, 45 minutes for 5 days a week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuro physical Therapy
Description: Routine neuro physical therapy will be given which includes Stretching, truck control and independent transition, train standing and activation of base, gain walking with minimal assistance, Gain ground clearance with stair climbing. for 45 minutes, 5 days a week for 8 weeks. Participants in group B will not be educated about treatment plan. Routine home plan was given in this group once in a week, for 8 weeks.
Study: NCT06150287

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Florajen Digestion
Description: Florajen Digestion is a probiotics. One probiotics capsule contains 15 billion Colony Forming Unit (CFU) of live microorganisms. No live microorganisms are present in the placebo capsules.
Study: NCT05889507

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follow up assessment at 2 years of age
Description: The assessment will be carried out using the Bayley Scales of Infant and Toddler Development IV. In addition, all infants will have a detailed neurological examination, including Gross Motor Function Classification System (GMFCS) for cerebral palsy, vision, and hearing assessment. Babies who die or who cannot be assessed with the Bayley-IV due to severe disability will be allocated a Cognitive Scale Composite score one point below the basal test score. PARCA-R will be completed by the parents immediately.
Study: NCT01890941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809 ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05384886

Intervention type: DIAGNOSTIC_TEST
Intervention: Polymerase chain reaction
Description: Covid-19 genetic material detection from mouth and nose swab

Intervention type: DIAGNOSTIC_TEST
Intervention: Polymerase chain reaction
Description: Covid-19 genetic material detection from mouth and nose swab
Study: NCT06558396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACE intervention
Description: Participants attend the ACE Program for 12 weeks after school. On one assigned day of the week, participants attend ACE in person after school. The session begins with mindfulness exercises (20 minutes), nutrition education lesson/cooking lab (65 minutes, odd weeks) OR professional development session (65 minutes, even weeks). On any day during the 2-week cooking period, the students will make a dish using groceries they received with their parent/guardian (1 hour).
Study: NCT05469035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile-based video
Description: Nurses in the experimental group participated in mobile-based video learning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face
Description: Nurses in the experimental group participated in face-to-face learning.
Study: NCT06150287

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Florajen Digestion
Description: Florajen Digestion is a probiotics. One probiotics capsule contains 15 billion Colony Forming Unit (CFU) of live microorganisms. No live microorganisms are present in the placebo capsules.
Study: NCT06016920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.16
Description: Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) starting at Week 1/Day 1 during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 48. A total of up to 10 i.m. administrations will be given.~VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.16
Description: Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) starting at Week 1/Day 1 during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 48. A total of up to 10 i.m. administrations will be given.~VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system.
Study: NCT06141928

Intervention type: OTHER
Group type: OTHER
Intervention: Functional recovery analysis
Description: Functional recovery analysis with force evaluator \& tester
Study: NCT06016920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.16
Description: Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) starting at Week 1/Day 1 during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 48. A total of up to 10 i.m. administrations will be given.~VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.16
Description: Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) starting at Week 1/Day 1 during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 48. A total of up to 10 i.m. administrations will be given.~VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.16
Description: Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) starting at Week 1/Day 1 during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 48. A total of up to 10 i.m. administrations will be given.~VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system.
Study: NCT06647641

Intervention type: OTHER
Intervention: Whole genome sequencing will be performed at the NIH
Description: All samples will undergo non-CLIA approved whole genome sequencing on a research basis in collaboration with Sonja Scholz, MD, PhD at the Neurodegenerative Diseases Research Unit of the National Institutes of Health (Bethesda, MD). This sequencing method allows for the identification of not only variants known to be associated with these disorders but also potentially novel variants.
Study: NCT05838651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MinerOss® X Plug
Description: A xenograft composed of 80% bovine cancellous particulate and 20% bovine Type I collagen.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MinerOss® X Plug
Description: A xenograft composed of 80% bovine cancellous particulate and 20% bovine Type I collagen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Striate+ Membrane
Description: A non-crosslinked collagen covering used to keep bacteria out and hold the bone graft in place.
Study: NCT05872594

Intervention type: DIAGNOSTIC_TEST
Intervention: Online questionnaire
Description: data will be collected remotely on the online platform Qualtrics
Study: NCT05640791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2；d1, 8, 21 d cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2；d1, 8, 21 d cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 100mg/m2；d1, 8, 21 d cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1000mg；d1, 21 d cycle
Study: NCT04835870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib-160mg bid PO d0-d20(1-21d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab-375 mg/m2 i.v d0 (/21d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide-750 mg/m2 i.v d1 (/21d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin-50 mg/m2 i.v d1 (/21d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine-1.4 mg/m2 i.v d1 (/21d)(2 mg max)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone-100 mg p.o d1-d5 (/21d)
Study: NCT05722795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 400 MG Oral Tablet
Description: One tablet daily 10 days before surgery.
Study: NCT05553678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam (0.03 mg/kg/30 min) will administered during UIA clipping through microscope.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (0.03 mg/ml/30 min) will administered during UIA clipping through microscope.
Study: NCT06220630

Intervention type: OTHER
Intervention: Breast cancer
Description: Male patients who were microscopically diagnosed as primary breast cancer.
Study: NCT04586686

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ovarian biopsy via laparoscopy
Description: A laparoscopy will be performed to achieve an ovarian cortical biopsy of one of both ovaries. Approximately twenty % of the ovarian volume as initially measured on the baseline ultrasound at the first visit will be removed to be processed in the lab for cortex freezing. The laparoscopic procedure in order to take the ovarian cortex biopsy will be standardised as much as possible. The technique developed by ProFam will be followed and adapted if needed by the surgeon's discretion. A three to four port laparoscopy will be used. The ovarian cortex biopsy will be taken using a curved scissor. Bipolar or unipolar cauterisation will be avoided as much as possible. If necessary for approximation or for hemostatic reasons, the ovarian edges can be stitched or Surgicel ® Absorbable Hemostat can be used.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ovarian biopsy via laparoscopy
Description: A laparoscopy will be performed to achieve an ovarian cortical biopsy of one of both ovaries. Approximately twenty % of the ovarian volume as initially measured on the baseline ultrasound at the first visit will be removed to be processed in the lab for cortex freezing. The laparoscopic procedure in order to take the ovarian cortex biopsy will be standardised as much as possible. The technique developed by ProFam will be followed and adapted if needed by the surgeon's discretion. A three to four port laparoscopy will be used. The ovarian cortex biopsy will be taken using a curved scissor. Bipolar or unipolar cauterisation will be avoided as much as possible. If necessary for approximation or for hemostatic reasons, the ovarian edges can be stitched or Surgicel ® Absorbable Hemostat can be used.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transvaginal oocyte retrieval
Description: After ovarian stimulation, a transvaginal oocyte retrieval will be performed either under local or general anaesthetics (patient's choice). The oocyte yield between the biopsied and non-biopsied ovary will be evaluated.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transvaginal oocyte retrieval
Description: After ovarian stimulation, a transvaginal oocyte retrieval will be performed either under local or general anaesthetics (patient's choice). The oocyte yield between the biopsied and non-biopsied ovary will be evaluated.
Study: NCT06364332

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Media campaign
Description: Participants receive content three times a week; in total 24 pieces of content in 8 weeks. The content can consist of one or more photos or images with a caption (explanation in text).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media campaign
Description: Participants receive content three times a week; in total 24 pieces of content in 8 weeks. The content can consist of one or more photos or images with a caption (explanation in text).
Study: NCT04801108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic or VATS lobar fissure completion
Description: The lobar fissure adjacent to the target lobe will be completed using a surgical stapler through robotic or video-assisted thoracic surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic or VATS lobar fissure completion
Description: The lobar fissure adjacent to the target lobe will be completed using a surgical stapler through robotic or video-assisted thoracic surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial valves placement
Description: Endobronchial valves will be placed in the target lobe after the fissure completion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial valves placement
Description: Endobronchial valves will be placed in the target lobe after the fissure completion.
Study: NCT06260579

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise/physical activity
Description: personalized exercise training and physical activity program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise/physical activity
Description: personalized exercise training and physical activity program
Study: NCT06164145

Intervention type: OTHER
Intervention: Usual care
Description: The training program used in this study is the stroke rehabilitation program focusing on health education for stroke and a routine exercise program based on the National Strategic Plan for Stroke Rehabilitation in Myanmar.